Used-car market dataset for Latvia 2018.
Ontology highlight
ABSTRACT:
SUBMITTER: Skribans V
PROVIDER: S-EPMC6362865 | biostudies-other | 2019 Feb
REPOSITORIES: biostudies-other
Similar Datasets
Project description:The commodity futures market plays a major role in reducing the price risk for the participants. Unfortunately, the farmers' participation in the futures market particularly from the Tamil Nadu region is very less. A survey was conducted using the interview method to identify the information sources used by farmers for taking pricing decisions, the awareness and perception of farmers towards the futures market, and its effect on preferred marketing alternatives. The data cleaning process was done using content validity, confirmatory factor analysis, and reliability test using Cronbach's alpha, and the assumptions of normality and multicollinearity were examined. The data will be of potential use to researchers who wish to explore farmers' behavior towards hedging in the commodity futures market.
| S-EPMC9278025 | biostudies-literature
Project description:The data presented in this article are related to the research article titled - "An exchange market pressure measure for cross country analysis" (Patnaik et al. [1]). In this article, we present the dataset for Exchange Market Pressure values (EMP) for 139 countries along with their conversion factors, ρ (rho). Exchange Market Pressure, expressed in percentage change in exchange rate, measures the change in exchange rate that would have taken place had the central bank not intervened. The conversion factor ρ can interpreted as the change in exchange rate associated with $1 billion of intervention. Estimates of conversion factor ρ allow us to calculate a monthly time series of EMP for 139 countries. Additionally, the dataset contains the 68% confidence interval (high and low values) for the point estimates of ρ's. Using the standard errors of estimates of ρ's, we obtain one sigma intervals around mean estimates of EMP values. These values are also reported in the dataset.
| S-EPMC5432674 | biostudies-literature
Project description:This article presents a dataset to investigate the determinants of firms' decision for primary share issuance and the effects of market timing on primary share issues in the Brazilian stock market. The data refer to Brazilian nonfinancial firms that issued primary shares (IPOs and SEOs) in the 2004-2015 period. The data were gathered from the online bases of Economatica® and the São Paulo Securities, Commodities and Futures Exchange (BM&FBovespa). The final sample was composed of 123 firms and 165 primary share issues: 97 initial public offerings and 68 follow-on offerings. The dataset was developed to support a model that captures market timing behavior through cumulative abnormal returns and shows the effects of this behavior on the amount of proceeds raised. The dataset contains subsamples and different analysis time windows, processed and unprocessed data. Researchers can use the dataset for future research and comparisons with other markets and models. The related research article using part of the current dataset was published under the following title: "Effects of market timing on primary share issues in the Brazilian capital market" (Gomes et al.).
| S-EPMC6661535 | biostudies-literature
Project description:The dataset represents a collection of real estate announcements published in 2018 in the Latvian leading advertisement website www.ss.com [1]. In the Latvian case, mentioned advertisement website is alternative information source in contrast with several (5-7) large real estate agencies. The mentioned advertisement website has no important competitors in Latvia, closer competitor reklama. lv [2] is 4-5 times smaller. Advertisement website www.ss.com represents information from small and medium size agencies, as well from individuals, who want to take part in the real estate market. The collected dataset reflects the observation dynamics of 12 months during 2018, including in total 238 thousand observations. Dataset has 24 dimensions, such as in announcement mentioned price for real estate, deal types, dimensions of location of real estate, such as region, district, address; characteristics of real estate, such as real estate type (land, flat and so on), size and main characteristics for each real estate type, such as land area or bad rooms in apartments. The dataset is hosted in Data Archiving and Networked Services (DANS) repository [3].
| S-EPMC7096678 | biostudies-literature
Project description:Nighttime light (NTL) data from the Defense Meteorological Satellite Program (DMSP)/Operational Linescan System (OLS) and the Visible Infrared Imaging Radiometer Suite (VIIRS) on the Suomi National Polar-orbiting Partnership satellite provide a great opportunity for monitoring human activities from regional to global scales. Despite the valuable records of nightscape from DMSP (1992-2013) and VIIRS (2012-2018), the potential of the historical archive of NTL observations has not been fully explored because of the severe inconsistency between DMSP and VIIRS. In this study, we generated an integrated and consistent NTL dataset at the global scale by harmonizing the inter-calibrated NTL observations from the DMSP data and the simulated DMSP-like NTL observations from the VIIRS data. The generated global DMSP NTL time-series data (1992-2018) show consistent temporal trends. This temporally extended DMSP NTL dataset provides valuable support for various studies related to human activities such as electricity consumption and urban extent dynamics.
| S-EPMC7272434 | biostudies-literature
Project description:Vehicle detection is a very important aspect of computer vision application to aerial and satellite imagery, facilitating activities such as instance counting, velocity estimation, traffic predictions, etc. The feasibility of accurate vehicle detection often depends on limited training datasets, requiring a lot of manual work in collection and annotation tasks. Furthermore, there are no known publicly available datasets. Our aim was to construct a pipeline for synthetic dataset generation from aerial imagery and 3D models in Blender software. The dataset generation pipeline consists of seven steps and results in a wished number of images with bounding boxes in YOLO and coco formats. This synthetic dataset has been produced following the steps described in this pipeline. It consists of 5000 2048 × 2048 images with cars inserted into the roads and highways at the images without cars from all over the world. We believe that this dataset and the respective pipeline might be of great importance for vehicle detection, facilitating the customizability of the models to specific needs and context.
| S-EPMC10875228 | biostudies-literature
Project description:ImportanceBoth the commercial sector and academia play a vital role in medicine development. Ongoing debates exist on their contribution and the value of medicinal products entering the market.ObjectiveTo identify the provenance and clinical benefit of medicines that entered the French market between 2008 and 2018.Design and settingIn this cross-sectional study, the provenance of each medicine in the French market was established via a review of multiple sources documenting at least 2 matching findings per product. The clinical benefit was assigned using the matched scale developed from the Prescrire and Haute Autorité de Santé (HAS) gradings. The χ2 test was used to analyze the proportions and frequencies of medicines graded by Prescrire and HAS by origin, therapeutic category, and clinical benefit.Main outcomes and measuresThe origins and therapeutic categories of medicines. Clinical benefit based on Prescrire and HAS grading. Concordance of Prescrire and HAS grading.ResultsOf the 632 medicines that entered the French market between 2008 and 2018, 464 originated (73%) in the commercial sector, and 168 originated (27%) in the academic setting or in collaboration with commercial enterprises. Prescrire graded psychotropic agents (13/14 [93%]), whereas HAS graded respiratory agents (24/25 [96%]) as the highest percentage of medicines that provided no added benefit. Prescrire graded 360 medicines (77.6%) that originated in the industry and 108 medicines (64.3%) that originated in the academic setting (P = .001) to have no added clinical benefit. HAS assigned such grading to 331 ([71.3%] industry) vs 104 ([61.9%] academia) (P = .02). Based on the Prescrire grading, academia invented more medicines delivering some added benefit 57 (33.9%) vs 98 (21.1%) invented by industry (P = .001). HAS grading on some added benefit 51 ([30.4%] academia) vs 121 ([26.1%] industry) did not reach statistical significance (P = .29). However, HAS grading on substantial added clinical benefit reached statistical significance in favor of academia (13 [7.7%] vs 12 [2.6%] in the industry; P = .003), whereas Prescrire grading did not (1.8% academia vs 1.3% industry; P = .64).Conclusions and relevanceMore than 70% of medicines that entered the French market during the 10-year period originated in the commercial sector. Although most medicines were not graded as providing clinical benefit, medicines originating in the academic setting were more likely to be graded as conferring clinical benefit than those originating in the commercial setting.
| S-EPMC10660249 | biostudies-literature
Project description:This data article revealed data about the UK long-term insurance market performance for over a decade. The data was acquired from the ABI and contains important trading results (i.e. premiums generated) across different types of long-term insurance. It also revealed the outgoings (i.e. claims incurred) and data on total individual business in force at year end - relating to number of policies. The data relates specifically to life and annuities, individual pensions, occupational pensions, income protection and other insurance business. The dataset revealed some important information on long-term insurance products within the UK insurance market which could serve as a high-quality resource for longitudinal analysis in the field. Thus, the data can provide crucial insights about UK long-term insurance market resilience during the global financial crisis and can be compare with different era, sectors and countries to show hidden business resilience factors, competitiveness and survival strategies.
| S-EPMC6280597 | biostudies-literature
Project description:Importance:The mean cost of developing a new drug has been the subject of debate, with recent estimates ranging from $314 million to $2.8 billion. Objective:To estimate the research and development investment required to bring a new therapeutic agent to market, using publicly available data. Design and Setting:Data were analyzed on new therapeutic agents approved by the US Food and Drug Administration (FDA) between 2009 and 2018 to estimate the research and development expenditure required to bring a new medicine to market. Data were accessed from the US Securities and Exchange Commission, Drugs@FDA database, and ClinicalTrials.gov, alongside published data on clinical trial success rates. Exposures:Conduct of preclinical and clinical studies of new therapeutic agents. Main Outcomes and Measures:Median and mean research and development spending on new therapeutic agents approved by the FDA, capitalized at a real cost of capital rate (the required rate of return for an investor) of 10.5% per year, with bootstrapped CIs. All amounts were reported in 2018 US dollars. Results:The FDA approved 355 new drugs and biologics over the study period. Research and development expenditures were available for 63 (18%) products, developed by 47 different companies. After accounting for the costs of failed trials, the median capitalized research and development investment to bring a new drug to market was estimated at $985.3 million (95% CI, $683.6 million-$1228.9 million), and the mean investment was estimated at $1335.9 million (95% CI, $1042.5 million-$1637.5 million) in the base case analysis. Median estimates by therapeutic area (for areas with ?5 drugs) ranged from $765.9 million (95% CI, $323.0 million-$1473.5 million) for nervous system agents to $2771.6 million (95% CI, $2051.8 million-$5366.2 million) for antineoplastic and immunomodulating agents. Data were mainly accessible for smaller firms, orphan drugs, products in certain therapeutic areas, first-in-class drugs, therapeutic agents that received accelerated approval, and products approved between 2014 and 2018. Results varied in sensitivity analyses using different estimates of clinical trial success rates, preclinical expenditures, and cost of capital. Conclusions and Relevance:This study provides an estimate of research and development costs for new therapeutic agents based on publicly available data. Differences from previous studies may reflect the spectrum of products analyzed, the restricted availability of data in the public domain, and differences in underlying assumptions in the cost calculations.
| S-EPMC7054832 | biostudies-literature
Project description:ObjectivesThis study examines the length of time between when a patent application is filed in Canada for a new drug and when it is available for patients (time to market) and various components of that time. It also looks at whether various factors explain the time between patent application to New Drug Submission (NDS) and compares Canadian and American times. Drugs approved between 1 January 2014 and 31 December 2018 are examined.DesignDescriptive study.Data sourcesWebsites from Health Canada, Food and Drug Administration, Merck Index, United States Patent and Trademark Office, WHO and previously published articles.InterventionsNone.Primary and secondary outcomesThe primary outcomes are time to market, time from patent application to NDS (pre-NDS time), review time, time from approval to availability (postapproval time) and factors that may influence the pre-NDS time. The secondary outcome is a comparison of Canadian and American review times and times between patent application and approval.ResultsThere were 113 drugs available for analysis. The median time to market was 11.80 years (IQR 9.40-14.05). The component median times were pre-NDS 10 years (IQR 8.05-12.80), review time 0.96 years (IQR 0.75-1.15) and postapproval time 0.15 years (IQR 0.08-0.28). Less than 8% of the pre-NDS time was explained by the factors that were analysed in a multiple linear regression equation. There was no statistically significant difference between Canadian and American pre-NDS times.ConclusionOnce a drug reaches the market, companies have a median of 8.2 years before the patent expires and generics can reach the market. Most of the time between the filing of a patent application and when a drug is marketed is determined by decisions that are largely under the control of the company.
| S-EPMC8258566 | biostudies-literature